DESCRIPTION
APPAVISC HV PFS (Hydroxypropyl Methylcellulose Ophthalmic Solution USP) is sterile, a pyrogen free clear & transparent viscous solution of highly purified HPMC. The chemical name of active ingredient is Cellulose 2- Hydroxypropyl Methyl Ether. Each mL contains: Hydroxypropyl Methylcellulose USP 2% w/v & Sterile isotonic base q.s.
MODE OF ACTION(Mechanismof Action)
HPMC consists of large macromolecules that exert a protective effect on ocular tissue during surgical procedures. It limits the mechanical damage from invasive procedures by separating and lubricating tissues. The HPMC also shows to decrease the damage of corneal endothelial cell loss during surgery. It is routinely used as an adjuvant in cataract surgery, IOL, corneal transplantation and surgery of glaucoma. HPMC goes well with the lens and other corneal surfaces because of its low contact angle.
INTENDED USE
APPAVISC HV PFS is indicated as a surgical aid (medical device) during surgical procedures involving the anterior chamber of the eye, including extraction of the lens and insertion of intraocular lenses. It maintains the depth of the anterior chamber during the whole surgical procedure and permits greater operative precision without the risk of damaging the endothelium of the cornea or other intraocular tissues.
CONTRAINDICATIONS
APPAVISC HV PFS is contraindicated in patients with glaucoma and Contraindicated in patients with known history hypersensitivity to its ingredients.
WARNING
Do not use if the solution becomes dark brown or any floating particles are observed If pouch is damaged should not be reused. In-case of any serious accident in relation to the device, inform to the manufacturer and to the regulatory authority.
PRECAUTIONS
GENERAL Overfilling of APPAVISC HV PFS in anterior chamber should be avoided as it may raise IOP & cause glaucoma. APPAVISCHV PFS is to be removed out of eye after the surgery by irrigation or aspiration. IOP should be monitored, especially after the end of surgery. If IOP is recorded, the appropriate therapy should be employed. APPAVISCHV PFS should be introduced in anterior chamber such that no air bubble should be trapped in HPMC. Vials and cannula once used should be discarded.
DRUG INTERACTIONS
Since HPMC is an inert substance and does not have any pharmacological action, no evidence suggests that the drug in intraocular milieu bind to APPAVISC HV PFS solution to any significant degree. There is no evidence of drug binding established so far.
PREPARATION & ADMINISTRATION GUIDE
APPAVISC HV PFS should be held at room temperature for approximately 30 minutes before use. Protect from freezing and exposure to light. For intraocular use
1.Remove the syringe from its packaging in a sterile environment
2. Open the syringe, withdraw the solution using sterile disposable syringe
3. Open the cannula and firmly screw it onto the lock fitting
4. Depress the plunger and discard the first 0.1 to 0.3 ml of fluid
5. Do not overfill the eye chamber with APPAVISCHV PFS.
6.. At the closing of procedure, irrigate the bulk of the APPAVISCHV PFS out of the anterior chamber with Balanced Salt Solution (BSS).
SIDE EFFECTS
APPAVISC HV PFS has the risk of IOP elevation. The viscoelastic substances that are not removed from the eye after surgery is not degraded to any significant degree when in the anterior chamber. It obstructs the outflow mainly trabucular meshwork into schlemm’s canal. A spike of IOP is more likely to occur in early hours of surgery(maximum 4-7 hours and often returns to baseline 24 hours). Residual effect of retained Viscoelastic material in anterior chamber should be considered in the differential diagnosis of corneal edema.
Severe corneal edema may occur due to thiomersal residues of reused Viscoelastic cannulas. There is a significant cell death at 30 minutes and near complete cell deaths at 2 hours if viscoelastic reused cannulas are used. Severe corneal edema may occur if the contact time of the viscoelastics with corneal endothelium by using reused cannula, following instillation, Additional events occurring includes corneal staining, keratopathy/keratitis, allergic reactions, lid edema, tearing, photophobia, corneal infiltrates, nausea and decreased vision.